Square Pharmaceuticals (SQURPHARMA) Q2 2025 earnings summary

Executive summary

• Consolidated net revenue for July–December 2024 rose to Tk. 37.72 billion, up 6.1% year-over-year, with net profit after tax reaching Tk. 12.70 billion, a 13% increase from the prior year.

• Standalone net revenue for Square Pharmaceuticals PLC was Tk. 29.90 billion, with net profit after tax of Tk. 7.85 billion for the six months ended December 2024.

• Earnings per share (EPS) for the group increased to Tk. 14.32 from Tk. 12.69 year-over-year; standalone EPS was Tk. 8.85, down from Tk. 10.37.

Financial highlights

• Gross profit for the group was Tk. 17.82 billion, up from Tk. 17.47 billion year-over-year; gross margin remained strong.

• Operating profit for the group reached Tk. 10.99 billion, with profit before tax at Tk. 13.39 billion, both higher than the previous year.

• Net asset value (NAV) per share for the group increased to Tk. 145.52 from Tk. 142.05; standalone NAV per share was Tk. 117.33.

• Net operating cash flow per share for the group declined to Tk. 8.28 from Tk. 14.37 year-over-year due to absence of one-off collections and insurance claims.

• Cash and cash equivalents for the group stood at Tk. 57.75 billion as of December 31, 2024.

Outlook and guidance

• Management expects continued business growth, with assets performing as intended and no significant seasonal or cyclical sales variations.

• No significant post-period events or changes in business outlook were reported.